InflammaDry® is the only rapid, in-practice test to aid in dry eye diagnosis
Identifying Dry Eye
Inflammation is linked to dry eye and is present in both symptomatic and asymptomatic patients.1 Elevated MMP-9 levels act as a biomarker for inflammation and is more sensitive at detection than clinical signs alone.2
InflammaDry® recognises elevated levels of MMP-9 to identify patients that may otherwise be missed with other dry eye testing methods. InflammaDry® is the first and only, rapid, in-practice test that detects MMP-9, an inflammatory marker that is consistently elevated in the tears of patients with Dry Eye Disease. Commit to making the right diagnosis with an easy-to-use, in-practice, dry eye test that gives accurate results in as little as 10 minutes.
By identifying and treating patients with dry eye, pre-surgical measurements are more accurate and post surgical outcomes are improved. It also reduces post-surgical complications, such as corneal wound healing, by identifying dry eye prior to surgery. And the therapeutic treatment of dry eye will improve patient quality of life.
What makes InflammaDry unique
Detects elevated levels of MMP-9 in tear fluid, to identify inflammation.
Provides rapid results, as soon as 10 minutes.
Accurate, with higher sensitivity and specificity, than other dry eye tests.
Disposable, in-practice diagnostic test that requires just 4 easy steps.
Low cost test requires no additional equipment to administer or interpret.
Get the right diagnosis
Find out how to use InflammaDry for the best results by watching this demonstration or reading the instructions.
Our Downloads
InflammaDry® Package Insert
PDF, 6MB
Studies on MMP-9 and Dry Eye Disease
PDF, 1MB
InflammaDry Point of Care Testing
PDF, 535KB
New Tools for Dry Eye Management
PDF, 147KB
Interested in using InflammaDry in your practice?
Contact us to find out more about InflammaDry and to order.
References
1.M.D.P. Willcox et al. The Ocular Surface. TFOS DEWS II Tear Film Report. 15 (2017) 366e403
2.Kaufman H. The practical detection of mmp-9 diagnoses ocular surface disease and may help prevent its complications. Cornea 2013;32:211–216
Read the news on
Positive Impact
The opticians’ favourite lens cleaning system is now more accessible than ever. We’ve removed the barrier of initial capital investment so you can focus on patient loyalty and practice growth.
Positive Impact (PI) will be showing its independent-only portfolio and launching two new diagnostic instruments.
This will be the debut for the return of the Keratron topographer range to the UK.
Throughout the month, more than 250 dry eye specialist practices across the UK joined forces with Positive Impact to help raise awareness of this growing eye health epidemic among the general public.